EricJLoweMD

Pediatric Hematology & Oncology • Norfolk, VA

Associate Professor, Pediatrics, Eastern Virginia Medical School

Join to view full profile

Dr. Lowe is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Lowe's full profile

Already have an account?

Office
601 Childrens Ln
Norfolk, VA 23507
Phone+1 757-668-7243

Fax+1 757-668-7811
Is this information wrong?

Education & Training

University of TennesseeFellowship, Pediatric Hematology/Oncology, 2001 - 2004
University of Texas Southwestern Medical CenterResidency, Pediatrics, 1998 - 2001
Emory University School of MedicineClass of 1998

Certifications & Licensure

VA State Medical License 2004 - 2026
NC State Medical License 2020 - 2022
TN State Medical License 2001 - 2006
TX State Medical License 1999 - 2002
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com
Fellow (FAAP) American Academy of Pediatrics

Clinical Trials

Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Start of enrollment: 2001 Feb 01
Unknown status
Phase 3
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma Start of enrollment: 2001 Oct 18
Active, not recruiting
Phase 3
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma Start of enrollment: 2004 Sep 04
Completed
Phase 3
Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors Start of enrollment: 2004 Mar 25
Recruiting
Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma Start of enrollment: 2004 Apr 01
Active, not recruiting
Phase 3
Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma Start of enrollment: 2005 Nov 14
Completed
Phase 3
Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer Start of enrollment: 2006 Feb 20
Completed
Phase 3
Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor Start of enrollment: 2007 May 03
Completed
Phase 3
Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors Start of enrollment: 2006 Jun 01
Completed
Phase 2
Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor Start of enrollment: 2006 Oct 30
Active, not recruiting
Phase 3
Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma Start of enrollment: 2006 Dec 26
Completed
Phase 3
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Start of enrollment: 2007 Mar 01
Completed
Phase 3
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Start of enrollment: 2007 Mar 01
Completed
Phase 1, Phase 2
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor Start of enrollment: 2007 Feb 26
Active, not recruiting
Phase 3
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia Start of enrollment: 2007 Mar 01
Completed
Phase 3
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET Start of enrollment: 2007 Mar 26
Active, not recruiting
Phase 3
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma Start of enrollment: 2007 Jan 22
Active, not recruiting
Phase 3
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin Start of enrollment: 2007 May 01
Completed
Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2008 Jan 15
Active, not recruiting
Phase 3
Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Start of enrollment: 2008 Jun 23
Completed
Phase 3
Neuropsychological and Behavioral Testing in Younger Patients With Cancer Start of enrollment: 2009 Feb 27
Recruiting
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Start of enrollment: 2009 Jan 01
Completed
Phase 2
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Start of enrollment: 2009 Mar 01
Completed
Phase 2
Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma Start of enrollment: 2006 Sep 25
Completed
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer Start of enrollment: 2003 Oct 13
Completed
Study of Kidney Tumors in Younger Patients Start of enrollment: 2006 Feb 27
Recruiting
Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma Start of enrollment: 2008 Feb 04
Completed
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma Start of enrollment: 2008 Feb 04
Completed
Collecting and Storing Biological Samples From Young Patients With Hodgkin?s Lymphoma Start of enrollment: 2006 Oct 23
Completed
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma Start of enrollment: 2000 Nov 06
Recruiting
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma Start of enrollment: 1999 Mar 15
Completed
Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors Start of enrollment: 2004 Feb 16
Completed
Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor Start of enrollment: 2009 Jul 13
Active, not recruiting
Phase 3
Study of Blood Samples From Newborns With Down Syndrome Start of enrollment: 2009 Feb 23
Completed
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Start of enrollment: 2009 Sep 14
Active, not recruiting
Phase 3
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma Start of enrollment: 2005 May 30
Completed
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma Start of enrollment: 2010 Jan 01
Completed
Phase 2
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma Start of enrollment: 2010 May 07
Active, not recruiting
Phase 3
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Start of enrollment: 2010 Jun 01
Terminated
Phase 3
Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2010 Aug 09
Completed
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia Start of enrollment: 2011 Feb 01
Completed
Phase 2
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma Start of enrollment: 2010 Aug 09
Active, not recruiting
Phase 3
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Start of enrollment: 2010 Nov 22
Completed
Phase 2
Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma Start of enrollment: 2010 Oct 01
Completed
Phase 2
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma Start of enrollment: 2010 Nov 22
Active, not recruiting
Phase 3
Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia Start of enrollment: 2011 Apr 04
Completed
Phase 3
Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation Start of enrollment: 2011 Sep 01
Completed
Phase 3
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Jun 20
Active, not recruiting
Phase 3
A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum Start of enrollment: 2012 Feb 01
Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients Start of enrollment: 2012 Jun 01
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma Start of enrollment: 2013 Feb 12
Completed
Phase 2
Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas Start of enrollment: 2013 Jun 17
Active, not recruiting
Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients. Start of enrollment: 2013 Aug 20
Completed
Phase 2
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma Start of enrollment: 2013 Nov 13
Active, not recruiting
Phase 2
Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma Start of enrollment: 2014 Aug 01
Completed
Phase 2
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Start of enrollment: 2014 Jul 11
Active, not recruiting
Phase 2, Phase 3
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Start of enrollment: 2009 Sep 01
Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer Start of enrollment: 2017 Nov 29
Recruiting
Phase 3
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma Start of enrollment: 2019 Jul 08
Active, not recruiting
Phase 2
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Start of enrollment: 2019 Jul 03
Recruiting
Phase 3
Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia Start of enrollment: 2020 Apr 06
Active, not recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma Start of enrollment: 2023 Aug 14
Recruiting
Phase 3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

2 citations
Children's Oncology Group's 2023 blueprint for research: Non-Hodgkin lymphoma.
Nader Kim El-Mallawany, Sarah Alexander, Mark Fluchel, Robert J Hayashi, Eric J Lowe, Lisa Giulino-Roth, Birte Wistinghausen, Michelle Hermiston, Carl E Allen> ;Pediatric Blood & Cancer. 2023 Sep 1
2 citations
Cellular and humoral immunotherapy in children, adolescents and young adults with non-Hodgkin lymphoma.
Yaya Chu, Aliza Gardenswartz, Caroline Diorio, Lianna J Marks, Eric Lowe, David T Teachey, Mitchell S Cairo> ;Best Practice & Research. Clinical Haematology. 2023 Mar 1
12 citations
Crizotinib in Combination With Chemotherapy for Pediatric Patients With ALK+ Anaplastic Large-Cell Lymphoma: The Results of Children's Oncology Group Trial ANHL12P1.
Eric J Lowe, Anne F Reilly, Megan S Lim, Thomas G Gross, Lauren Saguilig, Donald A Barkauskas, Rui Wu, Sarah Alexander, Catherine M Bollard> ;Journal of Clinical Oncology. 2023 Apr 10
2 citations
ALK inhibitors for ALK-altered paediatric malignancies.
Laurence Brugières, Zeinab Afify, Eric J. Lowe> ;The Lancet. Oncology. 2021 Nov 12
32 citations
Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Ag...
Andrew D.J. Pearson, Elly Barry, Yael P. Mosse, Franca Ligas, Nick Bird, Teresa de Rojas, Zachary Franklin Zimmerman, Keith D. Wilner, Willi Woessmann, Susan L. Weiner...> ;European Journal of Cancer. 2021 Sep 15
39 citations
Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1.
Eric J. Lowe, Anne Reilly, Megan S. Lim, Thomas G. Gross, Lauren Saguilig, Donald A. Barkauskas, Rui Wu, Sarah Alexander, Catherine M. Bollard> ;Blood. 2021 Jul 1
10 citations
From bench to bedside: the past, present and future of therapy for systemic paediatric ALCL, ALK.
Hugo Larose, G. A. Amos Burke, Eric J. Lowe, Suzanne D. Turner> ;British Journal of Haematology. 2019 Jun 1
Spontaneous Remission of Monosomy 7 Six Years After Diagnosis.
Holly J. Edington, Eric J. Lowe> ;Journal of Pediatric Hematology/oncology. 2019 Apr 1
6 citations
Plasmacytoma-like Posttransplant Lymphoproliferative Disorder in a Pediatric Heart Transplant Recipient:
Sara Rhodes Proctor Short, Steven L. Cook, Andrew S. Kim, Jacqueline M. Lamour, Eric J. Lowe, William C. Petersen> ;Journal of Pediatric Hematology/oncology. 2016 Mar 1
50 citations
Advanced stage anaplastic large cell lymphoma in children and adolescents: Results of ANHL0131, a randomized phase III trial of APO versus a modified regimen with vinb...
Sarah Alexander, Jacqueline M. Kraveka, Sheila Weitzman, Eric J. Lowe, Lynette M. Smith, James C. Lynch, Myron Chang, Marsha C. Kinney, Sherrie L. Perkins, Joseph Lave...> ;Pediatric Blood & Cancer. 2014 Dec 1
Chronic myelogenous leukemia in a 4-year-old boy.
Louise Man, Armin Rashidi, Eric J. Lowe, Stephen I. Fisher> ;European Journal of Haematology. 2013 Sep 1
30 citations
Anaplastic Large Cell Lymphoma in Children and Adolescents
Eric J. Lowe, Thomas G. Gross> ;Pediatric Hematology and Oncology. 2013 Aug 13
6 citations
Potential therapies for anaplastic lymphoma kinase-driven tumors in children: progress to date.
Eric J. Lowe, Megan S. Lim> ;Paediatric Drugs. 2013 May 22
7 citations
MALT lymphoma of the lip
Kate N. B. Crandley, Maria A. Aguiar, Eric J. Lowe> ;Pediatric Blood & Cancer. 2011 Apr 1
6 citations
Efficacy of high-dose methotrexate, ifosfamide, etoposide and dexamethasone salvage therapy for recurrent or refractory childhood malignant lymphoma
John T. Sandlund, C H Pui, Hazem Mahmoud, Yinmei Zhou, Eric J. Lowe, Sue C. Kaste, Larry E. Kun, Matthew J. Krasin, Mihaela Onciu, Frederick G. Behm, Raul C. Ribeiro, ...> ;Annals of Oncology. 2011 Feb 1
MALT lymphoma of the lip.
Crandley, K.B., Aguiar, M.A., Lowe, E.J.> ;Pediatr Blood Cancer. 2010-12-01
47 citations
Clinicopathologic Features of Histiocytic Lesions following ALL, with a Review of the Literature
Eumenia Costa da Cunha Castro, Cristina Blazquez, Jaime Boyd, Hernan Correa, J-P. de Chadarevian, Raymond E. Felgar, Nicole Graf, Norman B. Levy, Eric J. Lowe, John T....> ;Pediatric and Developmental Pathology. 2010 May 1
82 citations
Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: Final results of children's cancer group study 5941
Eric J. Lowe, Richard Sposto, Sherrie L. Perkins, Thomas G. Gross, Jonathan L. Finlay, David L. Zwick, Minnie Abromowitch> ;Pediatric Blood & Cancer. 2009 Mar 1
14 citations
Aggressive Digital Papillary Adenocarcinoma in a 15-year-old Female.
Megan K. Bazil, Robert M. Henshaw, Alice L. Werner, Eric J. Lowe> ;Journal of Pediatric Hematology/oncology. 2006 Aug 1
52 citations
Childhood anaplastic large cell lymphoma has a high incidence of ALK gene rearrangement as determined by immunohistochemical staining and fluorescent in situ hybridisa...
Sherrie L. Perkins, Diane L. Pickering, Eric J. Lowe, David L. Zwick, Minnie Abromowitch, Ginny Davenport, Mitchell S. Cairo, Warren G. Sanger> ;British Journal of Haematology. 2005 Dec 1
15 citations
Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome in Children and Adolescents
Eric J. Lowe, Eric J Werner> ;Seminars in Thrombosis and Hemostasis. 2005 Dec 1
71 citations
Early complications in children with acute lymphoblastic leukemia presenting with hyperleukocytosis.
Eric J. Lowe, Ching-Hon Pui, Michael L. Hancock, Terrence L. Geiger, Raja B. Khan, John T. Sandlund> ;Pediatric Blood & Cancer. 2005 Jul 1
Anemia and a large abdominal tumor in an adolescent.
Eric J. Lowe, Jesse J. Jenkins, Fredric A. Hoffer, Thom E Lobe, Victor M. Santana> ;Pediatric Blood & Cancer. 2004 Feb 1
113 citations
T-cell alloreactivity dominates natural killer cell alloreactivity in minimally T-cell-depleted HLA-non-identical paediatric bone marrow transplantation
Eric J. Lowe, Victoria Turner, Rupert Handgretinger, Edwin M. Horwitz, Ely Benaim, Gregory A. Hale, Paul Woodard, Wing Leung> ;British Journal of Haematology. 2003 Oct 1
47 citations
Idiopathic thrombocytopenic purpura diagnosed during the second decade of life.
Eric J. Lowe, George R. Buchanan> ;The Journal of Pediatrics. 2002 Aug 1
Join now to see all

Lectures

Toxicity Profile of Brentuximab Vedotin in Combination with Chemotherapy for Newly Diagnosed Patients with ALK+ ALCL: A Children's Oncology Group Study ANHL12P1
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Crizotinib Combined with Chemotherapy in Pediatric ALK-Positive Anaplastic Large Cell LymphomaJanuary 5th, 2023
Adding Brentuximab Vedotin to Chemotherapy Improves Outcomes in Pediatric ALK-Positive ALCLMay 1st, 2021